Literature DB >> 11258789

CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.

R D Lopez1, E K Waller, P H Lu, R S Negrin.   

Abstract

A small proportion of human CD3+ T lymphocytes are known to co-express CD56, an antigen usually restricted in its expression to natural killer (NK) cells. Whereas the in vivo function of CD3+ CD56+ T cells remains unknown, we and others have previously shown that both in vitro and in vivo, these cells can mediate a significantly greater degree of MHC-unrestricted cytotoxicitv against a variety of human tumor cells when compared to either CD3+ CD56- T cells or lymphokine activated killer (LAK) cells. While the mechanismns regulating the in vivo expansion of CD56+ T cells are not known, here we demonstrate the importance of CD2-mediated IL-12-dependent signals in the in vitro expansion of CD56+ T cells. Specifically, we show that activated monocytes provide a contact dependent factor (CD58/LFA-3) and a soluble factor (IL-12), both critical for the in vitro expansion of CD56+ T cells. The biological and therapeutic implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258789     DOI: 10.1007/s002620000148

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  MicroRNA profiling of CD3+ CD56+ cytokine-induced killer cells.

Authors:  Wenju Wang; Ruhong Li; Mingyao Meng; Chuanyu Wei; Yanhua Xie; Yayong Zhang; Lihong Jiang; Ruiyi Dong; Chunhui Wang; Yiming Zhong; Fang Yang; Weiwei Tang; Xingfang Jin; Baohua Liu; Zongliu Hou
Journal:  Sci Rep       Date:  2015-03-31       Impact factor: 4.379

2.  Investigation on correlation between expression of CD58 molecule and severity of hepatitis B.

Authors:  Li Sheng; Jie Li; Bao-Tai Qi; Yu-Qiang Ji; Zhao-Jun Meng; Ming Xie
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Authors:  Leonard Christopher Schmeel; Frederic Carsten Schmeel; Christoph Coch; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

Review 4.  Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.

Authors:  Yiming Meng; Zhifu Yu; Yefeng Wu; Tianzhao Du; Shi Chen; Fanjuan Meng; Nan Su; Yushu Ma; Xiaoxi Li; Sulan Sun; Guirong Zhang
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

5.  The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome.

Authors:  Ming Xie; Ping Chen; Lin-Jing He; Bao-Tai Qi; Ping Wang; Xiao-Fang Wang; Hui-Xun Ren
Journal:  Clin Exp Med       Date:  2008-09-27       Impact factor: 3.984

Review 6.  Cytokine-induced NK-like T cells: from bench to bedside.

Authors:  Yeh Ching Linn; Kam M Hui
Journal:  J Biomed Biotechnol       Date:  2010-03-30

7.  Dynamic tracing of immune cells in an orthotopic gastric carcinoma mouse model using near-infrared fluorescence live imaging.

Authors:  Xiaohui DU; Xiangyu Wang; Ning Ning; Shaoyou Xia; Juchao Liu; Wentao Liang; Huiwei Sun; Yingxin Xu
Journal:  Exp Ther Med       Date:  2012-05-17       Impact factor: 2.447

Review 8.  Cancer Immunotherapy with Cytokine-Induced Killer Cells.

Authors:  Juan J Mata-Molanes; Manuel Sureda González; Belén Valenzuela Jiménez; Elena Mª Martínez Navarro; Antonio Brugarolas Masllorens
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.864

Review 9.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

Review 10.  Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma.

Authors:  Clara E Jäkel; Stefan Hauser; Sebastian Rogenhofer; Stefan C Müller; P Brossart; Ingo G H Schmidt-Wolf
Journal:  Clin Dev Immunol       Date:  2012-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.